Metabolic Pharmacology · Explainer
In a 48-week Phase 2 trial published in the New England Journal of Medicine, participants on the highest dose lost an average of 24.2% of their body weight — about 58 pounds. Nobody was put on a crash diet or a boot camp to get there. This page explains how one molecule does that, and what the trial does and doesn’t tell you.
Video · a physician’s walkthrough
Source: Dr. Ashley Froese, “This Is Not Covered” (YouTube). Independent educational content embedded for reference. Dr. Froese is not affiliated with this page and has not reviewed or endorsed it.
The short version
Body weight isn’t one system. It’s an argument between appetite, insulin, and energy expenditure — and for fifteen years the entire drug class has only been allowed to speak to the first one.
GLP-1 drugs like semaglutide are very good at that argument. They quiet hunger. But the body answers back: metabolic rate drifts down, the loss stalls, and the number on the scale settles somewhere short of where you wanted it.
Retatrutide was built to argue on three fronts at once. It is what pharmacologists call a triple agonist — a single molecule that keys into three different receptors, each governing a different piece of the same problem.
What the published trial reported
The three targets
Tells the brain you’ve eaten. Slows how fast the stomach empties, blunts food noise, steadies blood sugar. This is the one switch every GLP-1 drug pulls — and the only one some of them pull.
Changes how fat is stored and how well insulin does its job. It also appears to buffer the nausea that GLP-1 causes on its own — which is why the two-receptor drugs are often tolerated better, not worse, despite being stronger.
The one nobody could safely touch until now. It raises energy expenditure and pushes the liver to burn through its own stored fat. Every prior drug worked on intake. This is the first that also works on output.
Receptor coverage
Receptor targets as described in the published pharmacology. This chart shows what each molecule binds — not a comparison of results, safety, or suitability for any individual.
In the video
Glucagon raises blood sugar. Pairing it with two incretins is what makes it usable instead of dangerous — and why this molecule took so long to arrive.
What actually happens metabolically when a single-receptor drug stops working, and why adding hunger suppression on top of hunger suppression doesn’t fix it.
The dose-escalation logic, what the early weeks feel like, and the single most common mistake that sends people back to square one.
The contraindications and the personal-history questions worth answering honestly before anyone goes near a triple agonist.
Read this part first
If this section talks you out of it, it did its job.
Retatrutide is investigational. It has not been approved by the FDA or any comparable regulator, which means no pharmacy dispenses it and nothing sold today is sold as a treatment for anything. The trial results above came from Eli Lilly’s own pharmaceutical-grade compound, dosed under medical supervision — not from anything a third-party supplier ships. Treat those as two different things, because they are.
Nausea, vomiting, diarrhea, constipation, fatigue. They cluster around dose increases. Most people who quit this class quit during escalation, not because it stopped working.
A triple agonist is a bigger metabolic lever, not a gentler one. If a single-receptor drug already produced more side effects than you could live with, a third receptor is not the fix.
Rapid loss on any agonist takes lean mass with it unless protein intake and resistance training hold the line. The people who keep their results are the ones who trained through it.
None of this is medical advice, and no page can substitute for a clinician who knows your history. Talk to one.
Want to know more?
Got it.
We’ll text you shortly. Reply STOP any time to opt out.
Questions
No. It is an investigational compound still moving through late-stage clinical trials. It is not approved, not prescribable at a pharmacy, and not sold as a medicine. Anyone telling you otherwise is telling you something untrue.
Receptor count. Semaglutide (Ozempic, Wegovy) engages GLP-1. Tirzepatide (Mounjaro, Zepbound) engages GLP-1 and GIP. Retatrutide engages GLP-1, GIP and the glucagon receptor — adding an energy-expenditure arm that neither of the others has.
Yes. Like the rest of the class, it’s a subcutaneous injection, typically weekly, typically with a dose that steps up gradually rather than starting where it finishes. There is no oral version.
Predominantly gastrointestinal — nausea, vomiting, diarrhea, constipation — and most pronounced in the days after a dose increase. The video covers the tolerance curve in detail.
The standard incretin contraindications apply: a personal or family history of medullary thyroid carcinoma or MEN 2, prior pancreatitis, pregnancy or trying to conceive, and significant existing GI disease. If any of those describe you, this is a conversation with a physician, not a form.
You’ll get a text with more information. Nothing on this page sells anything, and you can reply STOP at any time to stop hearing from us.